1. Home
  2. RSI vs ACAD Comparison

RSI vs ACAD Comparison

Compare RSI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rush Street Interactive Inc.

RSI

Rush Street Interactive Inc.

N/A

Current Price

$26.46

Market Cap

3.6B

ML Signal

N/A

ACAD

ACADIA Pharmaceuticals Inc.

N/A

Current Price

$27.84

Market Cap

4.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
RSI
ACAD
Founded
2012
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
4.3B
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
RSI
ACAD
Price
$26.46
$27.84
Analyst Decision
Strong Buy
Buy
Analyst Count
10
22
Target Price
$28.20
$30.55
AVG Volume (30 Days)
1.9M
1.3M
Earning Date
04-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
933.33
69.12
EPS
0.19
0.20
Revenue
$1,134,428,000.00
$726,437,000.00
Revenue This Year
$25.44
$18.80
Revenue Next Year
$14.27
$11.70
P/E Ratio
$140.63
$138.40
Revenue Growth
22.76
40.45
52 Week Low
$15.51
$19.69
52 Week High
$34.53
$30.96

Technical Indicators

Market Signals
Indicator
RSI
ACAD
Relative Strength Index (RSI) 46.44 44.05
Support Level $26.00 $25.00
Resistance Level $27.23 $27.79
Average True Range (ATR) 1.03 0.75
MACD 0.25 -0.37
Stochastic Oscillator 53.73 14.48

Price Performance

Historical Comparison
RSI
ACAD

About RSI Rush Street Interactive Inc.

Rush Street Interactive Inc is an online gaming and entertainment company that focuses on online casinos and online sports betting in the U.S. and Latin American markets. It provides customers with an array of gaming offerings such as real-money online casinos, online sports betting, and retail sports betting, as well as social gaming, which involves free-to-play games that use virtual credits that can be earned or purchased. The company generates revenue by offering online casinos, online sports betting, and social gaming directly to the end customer through its websites or apps. The company generates revenue through business-to-consumer (B2C) and business-to-business (B2B) models.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: